The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.
Beta-blockers are currently contraindicated in asthma because their acute administration may be associated with worsening bronchospasm. However, their effects and safety with their chronic administration are not well evaluated. The rationale for this pilot study was based on the paradigm shift that was observed with the use of beta-blockers in congestive heart failure, which once contraindicated because of their acute detrimental effects, have now been shown to reduce mortality with their chronic use. We hypothesized that certain beta-blockers may also be safe and useful in chronic asthma therapy. In this prospective, open-label, pilot study, we evaluated the safety and effects of escalating doses of the beta-blocker, nadolol, administered over 9 weeks to 10 subjects with mild asthma. Dose escalation was performed on a weekly basis based on pre-determined safety, lung function, asthma control and hemodynamic parameters. The primary objective was to evaluate safety and secondary objectives were to evaluate effects on airway hyperresponsiveness, and indices of respiratory function. The escalating administration of nadolol was well tolerated. In 8 out of the 10 subjects, 9 weeks of nadolol treatment produced a significant, dose-dependent increase in PC20 that reached 2.1 doubling doses at 40 mg (P<0.0042). However, there was also a dose-independent 5% reduction in mean FEV1 over the study period (P<0.01). We conclude that in most patients with mild asthma, the dose-escalating administration of the beta-blocker, nadolol, is well tolerated and may have beneficial effects on airway hyperresponsiveness. Our findings warrant further testing in future larger trials.
Hanania
Nicola A
NA
Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA. Hanania@bcm.edu <Hanania@bcm.edu>
Singh
Supria
S
El-Wali
Rami
R
Flashner
Michael
M
Franklin
Amie E
AE
Garner
William J
WJ
Dickey
Burton F
BF
Parra
Sergio
S
Ruoss
Stephen
S
Shardonofsky
Felix
F
O'Connor
Brian J
BJ
Page
Clive
C
Bond
Richard A
RA
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009248:Nadolol / Q000008:administration & dosage* / Q000009:adverse effects*; D010865:Pilot Projects; D011446:Prospective Studies; D012129:Respiratory Function Tests
D000319:Adrenergic beta-Antagonists; D009248:Nadolol
Lancet. 1990 Dec 8;336(8728):1391-6
1978871
J Allergy Clin Immunol. 1993 Feb;91(2):643-50
8436777
Thorax. 1993 Feb;48(2):134-8
8493626
BMJ. 1993 Jun 12;306(6892):1610-1
8101115
Lancet. 1993 Oct 2;342(8875):833-7
8104272
J Am Coll Cardiol. 1995 Apr;25(5):1154-61
7897129
N Engl J Med. 1996 May 23;334(21):1349-55
8614419
N Engl J Med. 1996 Sep 19;335(12):841-7
8778601
Circulation. 1996 Dec 1;94(11):2807-16
8941106
Drug Saf. 1997 May;16(5):295-308
9187530
Circulation. 1998 Sep 22;98(12):1184-91
9743509
J Asthma. 1998;35(6):473-9
9751064
Am J Respir Crit Care Med. 1999 Jan;159(1):22-30
9872813
Lancet. 1999 Jan 2;353(9146):9-13
10023943
Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1043-51
10194144
Am Heart J. 1999 Jul;138(1 Pt 1):78-86
10385768
J Allergy Clin Immunol. 1999 Aug;104(2 Pt 2):S18-30
10452785
Nature. 2004 Nov 4;432(7013):7
15525951
Proc Am Thorac Soc. 2005;2(4):292-6; discussion 311-2
16267351
Chest. 2006 Jan;129(1):15-26
16424409
Ann Intern Med. 2006 Jun 20;144(12):904-12
16754916
Eur Respir J. 1999 Oct;14(4):902-7
10573240
Am J Respir Crit Care Med. 2000 Jan;161(1):309-29
10619836
JAMA. 2000 Mar 8;283(10):1295-302
10714728
Am J Respir Crit Care Med. 2000 Jul;162(1):75-80
10903223
Trends Pharmacol Sci. 2001 Jun;22(6):273-6
11395153
Nat Rev Drug Discov. 2002 Oct;1(10):825-9
12360260
Eur Respir J. 2002 Oct;20(4):853-8
12412675
J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S322-8
12464943
Chest. 2003 Jul;124(1):70-4
12853504
J Clin Invest. 2003 Aug;112(4):495-7
12925688
J Clin Invest. 2003 Aug;112(4):619-26
12925702
Am J Respir Med. 2003;2(4):287-97
14719995
Drug Saf. 2004;27(4):243-70
15003036
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4948-53
15069206
Ann Intern Med. 2004 May 18;140(10):802-13
15148067
Lancet. 2004 Oct 23-29;364(9444):1505-12
15500895
Br Heart J. 1975 Oct;37(10):1022-36
1191416
Br Heart J. 1976 May;38(5):537-8
1268019
Am Heart J. 1982 Apr;103(4 Pt 2):639-49
7064806
Br Med J. 1968 Feb 10;1(5588):335-9
5317525
Br Med J. 1968 Feb 10;1(5588):339-43
5317526
Am Rev Respir Dis. 1989 Jun;139(6):1390-4
2658700
Lancet. 1990 Jul 7;336(8706):1-6
1694945